The Top 5 Biosimilar Articles for the Week of September 6

Here are the top 5 biosimilar articles for the week of September 6, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of September 6, 2021.

Number 5: Policy developments, business milestones, and physician-led efforts to shape biosimilar absorption made August 2021 an active time for these lower-cost biologics.

Number 4: Animal toxicology studies still get included with biosimilar approval applications, although there are strong arguments that most of these studies are unnecessary. Sarfaraz K. Niazi, PhD, explained the pros and cons.

Number 3: Shanghai Henlius Biotech, Innovent Biologics, and other Chinese biopharmaceutical makers are leading the wave of Asia-Pacific (APAC) biosimilar development, according to a GlobalData analyst.

Number 2: Kaiser Permanente got biosimilars into circulation by building physician confidence, a strategy that a Samsung Bioepis executive said should be employed more widely.

Number 1: A meta-analysis of pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of Sandoz pegfilgrastim biosimilar confirmed biosimilarity.

To read all of these articles and more, visit centerforbiosimilars.com.